Qiagen NV

QGEN

45.280USD

-0.770-1.67%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

26 / 507

Overall Ranking

149 / 4724

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 18 analysts

Buy

Current Rating

51.783

Target Price

+14.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Fairly Valued

The company’s latest PE is 26.32, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 189.55M shares, increasing 3.39% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.16M shares of this stock.

The company's current financial score is 7.61, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 483.46M, representing a year-over-year increase of 5.37%, while its net profit experienced a year-over-year increase of 12.50%.

Score

Industry at a Glance

Previous score

7.61

Change

0



Financials

8.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.59

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.55

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.21

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.17

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is 27.90, which is 244.55% below the recent high of 96.12 and 6.13% above the recent low of 26.19.

Score

Industry at a Glance

Previous score

4.27

Change

0.03

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 26/507

No Data

The company’s current earnings forecast score is 7.44, which is lower than the Biotechnology & Medical Research industry's average of 7.96. The average price target for Qiagen NV is 52.00, with a high of 57.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

7.22

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.63, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 49.76 and the support level at 46.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.43

Change

-0.06

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 87.53%, representing a quarter-over-quarter increase of 5.87%. The largest institutional shareholder is The Vanguard, holding a total of 9.16M shares, representing 4.21% of shares outstanding, with 6.46% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Wellington Management Company, LLP

24.44M

+4.92%

MFS Investment Management

24.26M

--

BlackRock Institutional Trust Company, N.A.

20.17M

-1.71%

The Vanguard Group, Inc.

Star Investors

8.78M

+2.87%

T. Rowe Price International Ltd

4.15M

+2888.12%

EARNEST Partners, LLC

3.81M

--

Amundi Asset Management, SAS

4.19M

-10.96%

Swedbank Robur Fonder AB

3.06M

+6.51%

Norges Bank Investment Management (NBIM)

3.96M

-2.74%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 6.02, which is higher than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Qiagen NV

QGEN

6.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Protagonist Therapeutics Inc

PTGX

7.04 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.01 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.